# Carlsmed, Inc. (CARL)

> Source: Nexqual · https://nexqual.com/CARL · data as of 2026-11-18 20:53 UTC · cite as "Nexqual, Carlsmed, Inc. (CARL), nexqual.com/CARL" · informational, not investment advice.

**Price:** USD 17.44 (-1.72% today) · US market open, as of November 18, 2026 at 20:53 UTC; quotes may be delayed. Prev close 17.74 · day 17.32–18.26 · 52w 8.5–19.15 · market cap $478M · NMS

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $71.8M, net income -$40.1M (-55.8% margin), free cash flow -$34.9M (SEC filings).
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $29K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.60 on a 1–5 scale) (5 analysts), mean target USD 22 (range 18–26).
- Total return with dividends: 1Y +44.8% vs S&P 500 +11.8%; 5Y +22.3% vs S&P 500 +66.5%.
- Latest earnings report: 2026-11-10 (next date not yet announced).
- Dividend: CARL paid no cash dividend in the last five years.
- Short interest: 12.04% of float (as of 2026-10-30), 15.1 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2024 | FY2025 | TTM |
|---|---|---|---|
| Revenue | $27.2M | $50.5M | $71.8M |
| Gross profit | $20.0M | $38.0M | — |
| Operating income | -$24.1M | -$30.6M | -$42.3M |
| Net income | -$24.3M | -$29.6M | -$40.1M |
| EPS (diluted) | -$6.11 | -$2.12 | — |
| Free cash flow | -$25.6M | -$29.6M | -$34.9M |
| Gross margin | 73.8% | 75.3% | — |
| Operating margin | -88.8% | -60.5% | -59.0% |
| Net margin | -89.3% | -58.7% | -55.8% |
| Revenue growth | — | +85.9% | — |
| Cash + short-term investments | $40.1M | $110M | — |
| Total debt | $15.4M | $15.3M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/S 6.8x · EV/Sales 6.2x · P/B 6.4x · FCF yield -7.18% · Earnings yield -8.24% · Net cash $44.5M · EV $442M

## Insider sales (SEC Form 4, open-market, last ~7 months)
4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Bertolini Jeffrey | Chief Operating Officer | 747 | $11K | 3.2% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-10-30 | Bertolini Jeffrey | Chief Operating Officer | 243 | $4K | 1.1% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05 | Bertolini Jeffrey | Chief Operating Officer | 747 | $11K | 3.2% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-30 | Bertolini Jeffrey | Chief Operating Officer | 243 | $3K | 1.1% | Yes (adopted March 12, 2026) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.60 on a 1–5 scale), 5 analysts; mean target USD 22 (low 18, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-11 | Truist Securities | Target raised | Buy | $20 → $23 |
| 2026-11-11 | Needham | Target raised | Buy | $17 → $22 |
| 2026-11-11 | BTIG | Target raised | Buy | $24 → $26 |
| 2026-10-12 | BTIG | Target raised | Buy | $23 → $24 |
| 2026-09-28 | BTIG | Reiterated | Buy | $23 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $18 → $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2025-07-21) |
|---|---|---|
| Total return | +44.8% | +22.3% |
| S&P 500 (SPY) | +11.8% | +66.5% |
| Per year | +44.9% | +16.4% |
| Volatility (annualized) | 74.6% | 65.4% |
| Max drawdown | -48.0% (Dec 2025→Apr 2026) | -45.1% (Nov 2025→Apr 2026) |

## Dividends
CARL paid no cash dividend in the last five years.

## Short interest
1,241,498 shares sold short, 12.04% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,053,927 shares (+17.8%). Days to cover: 15.1 (short shares ÷ average daily volume).

## Peers (Health Information Services)
HTFL (Heartflow, Inc.) USD 46.01 -2.25% · EVH (Evolent Health, Inc) USD 3.95 -14.50% · NRC (NRC Health) USD 26.06 +0.68% · CTEV (Claritev Corporation) USD 21.95 -4.35% · SOPH (SOPHiA GENETICS SA) USD 7.47 +0.27% · PHR (Phreesia, Inc.) USD 12.31 -1.99%

## More
Full page: https://nexqual.com/CARL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in CARL's own 10-K filed 2026-02-25 (https://www.sec.gov/Archives/edgar/data/1794546/000119312526071551/carl-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Johnson & Johnson (JNJ) | "Our products currently compete with stock implants manufactured or developed by other companies, including Medtronic PLC, Johnson & Johnson, and Globus Medical Inc. Some of these competitors are large, well-capitalized c…" |

## Customer concentration

In the quarter ended Mar 31, 2025, a single direct customer accounted for 10% of CARL's revenue. The company does not name this customer in the filing. (10-Q, filed 2026-05-05)

## Company outlook (8-K filed 2026-11-10)

- "Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.39 | $-0.40 | +$0.01 | $19.2M | 2 |
| Next quarter (ends 2026-12-31) | $-0.35 | $-0.30 | −$0.04 | $24.3M | 1 |
| Current fiscal year (ends 2026-12-31) | $-1.51 | $-1.41 | −$0.10 | $79.3M | 1 |
| Next fiscal year (ends 2027-12-31) | $-1.56 | $-1.38 | −$0.18 | $111.9M | 1 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.11 | −$0.38 | Beat +71.1% | — |
| — | Quarter ended Jun 30, 2026 | −$0.39 | −$0.39 | In line | — |
| — | Quarter ended Mar 31, 2026 | −$0.26 | −$0.39 | Beat +33.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.29 | −$0.43 | Beat +32.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-10 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000026/0001794546-26-000026-index.htm |
| 2026-11-10 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000025/0001794546-26-000025-index.htm |
| 2026-09-30 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure — “Departure of Chief Financial Officer On September 28, 2026, Carlsmed, Inc. (the "Company") announced that Leo Greenstein has departed his role as the Company's Chief Financial Officer, effective September 25, 2026 (the "Separation Date"). The Company appreciates Mr. Greenstein's contributions and wishes him well in his future endeavors. Mr. Greenstein's departure is not a result of any disagreement with the Company's independent auditors or any member of management on any matter of accounting principles or…” | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000020/0001794546-26-000020-index.htm |
| 2026-09-08 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure — “On September 4, 2026, the Board of Directors of Carlsmed, Inc. (the "Company") appointed Jeffrey Bertolini as Chief Operating Officer of the Company, effective September 8, 2026. Mr. Bertolini, age 60, has served as the Company's Senior Vice President, Operational Excellence since March 2025. Previously, Mr. Bertolini was Vice President of Advanced Manufacturing Technologies of the Company from September 2024 to March 2025. Before joining the Company, Mr. Bertolini was Senior Vice President, Operations &…” | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000018/0001794546-26-000018-index.htm |
| 2026-08-05 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000016/0001794546-26-000016-index.htm |
| 2026-08-05 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1794546/000179454626000015/0001794546-26-000015-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
